Compensated Vaccine Research Studies
Researchers at the WRAIR Clinical Trials Center are partnering with individuals for research studies aimed at confirming the safety & tolerability of vaccines.
Research Conducted in Silver Spring, MD
Compensation Up To $1,980
12-Month Research Studies
In Good Health
18-49 Years Old
Fast Facts
Study Background
Our researchers want to learn more about the efficacy of vaccines for the Hantaan and Puumala viruses.
The Hantaan and Puumala viruses can be found all over the world and have no specific treatments or FDA-approved vaccines.
Join one of our studies and contribute to important vaccine research!
The Hantaan and Puumala viruses can be found all over the world and have no specific treatments or FDA-approved vaccines.
Join one of our studies and contribute to important vaccine research!
Additional Information
The main purpose of this study is to confirm that these vaccines are safe and tolerable. Another purpose of this study is to see if this experimental vaccine helps your body to make the antibodies that protect against the Hantaan and Puumala viruses. The experimental vaccines used in this study have been tested in a smaller, previous study and were shown to be safe. This study will look at two different vaccines that are designed to help protect against the Hantaan and Puumala viruses.
You may qualify for this study if you meet the following criteria.
Eligibility Criteria:
Eligibility Criteria:
- 18 and 49 years old.
- In good health.
- Be a male or non-pregnant, non-lactating female.
- If you are a female: you must agree to consistently use effective birth control at least 30 days before the first vaccination and through 3 months after the last vaccination. You must also agree not to donate eggs from screening until 90 days after the last study vaccination.
- If you are male: you must agree not to father a child or donate sperm from screening until 90 days after the last vaccination.
- You must agree not to participate in another clinical trial during the study.
The vaccinations will be given by trained staff in the upper, outer part of the arm, using a needle-free device called the Pharmajet Stratis® injector device.
Each vaccination group will receive a series of 4 intramuscular vaccinations. The safety of each vaccine dose will be closely monitored. If after administration of the vaccine, it is determined to be too risky to your health, you will not continue to get any more of these vaccinations.
There will be several follow-up visits after each vaccination. During the follow-up visits your vital signs are taken, there is a review of your medical history since your last visit, a discussion of any symptoms you might be experiencing, and blood may be drawn for testing.
Each vaccination group will receive a series of 4 intramuscular vaccinations. The safety of each vaccine dose will be closely monitored. If after administration of the vaccine, it is determined to be too risky to your health, you will not continue to get any more of these vaccinations.
There will be several follow-up visits after each vaccination. During the follow-up visits your vital signs are taken, there is a review of your medical history since your last visit, a discussion of any symptoms you might be experiencing, and blood may be drawn for testing.
You will receive financial compensation for your time and effort. The compensation you will receive ranges from $50 at screening to $200 for vaccination visits. If you make all of the scheduled visits, the maximum compensation you can receive by participating a study is $1980.